Equity Overview
Price & Market Data
Price: $0.258
Daily Change: -$0.00452 / 1.75%
Daily Range: $0.253 - $0.265
Market Cap: $325,397,792
Daily Volume: 1,324,265
Performance Metrics
1 Week: -13.46%
1 Month: -18.35%
3 Months: -26.57%
6 Months: 11.26%
1 Year: 96.20%
YTD: 109.6%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.